Page 1,662«..1020..1,6611,6621,6631,664..1,6701,680..»

‘Small Town Throwdown’ will benefit Zach Standen – Easton Courier

Posted: February 22, 2017 at 10:43 pm

Bobby Paultauf and his band will play the throwdown.

Those in the Redding, Easton area are probably aware of what happened to Joel Barlow High School student Zach Standen in the summer of 2016. Zach was in a devastating auto accident that left him partially paralyzed.

He needs hope and support from as many people as possible. He needs countless medical procedures in order to gain movement to his legs again through stem cell treatment due to a tragic car accident that made him paralyzed.

To help support Standens recovery, local musicians Bobby Paltauf, of the Bobby Paltauf Band, and Grayson Hugh, of Grayson Hugh & the Moon Hawks, will play a benefit show on Saturday, March 11 at the Fairfield Theater Company.

The family has started a GoFundMe account where people are able to donate to this expensive treatment. Lets all get together and help him walk again, Paultaufs mother, Tiffany, wrote in a press release.

Bobby Paltauf is a senior at Joel Barlow High School, where Standen goes.

Lets all get together and support local live music, especially where it benefits the hope of Zach being able to walk again, his mother wrote.

For the concert benefitting Standen, more information can be found on The Bobby Paltauf Band page on Facebook, and tickets are available at http://www.fairfieldtheatre.org.

Standen may be helped by stem cell medical treatments that can be administered in Panama.

The Standen family is in discussions and communication with the Cell Medicine Institute in that country and are pursuing this line of treatment for the young man, who is paralyzed.

We have done much research into stem cell therapy for spinal cord injuries here in the U.S. and Canada, and there just are no clinical trials or clinics that have the experience and track record like this one, the family said in a recent letter. Cell Medicine has been doing this specific treatment since 2006 and has a 60% to 70% success rate of some kind of improvements in most patients within a year.

Each procedure costs $37,200, which includes all medical procedures and ancillary needs. This is not covered by medical insurance.

The family is hoping everyone reading this could go to his GoFundMe page and donate $25, to help Zachs recovery.

To donate, visit: https://www.gofundme.com/stem-cell-therapy-for-zach-standen.

Excerpt from:
'Small Town Throwdown' will benefit Zach Standen - Easton Courier

Posted in Cell Medicine | Comments Off on ‘Small Town Throwdown’ will benefit Zach Standen – Easton Courier

Hear This: Scientists Regrow Sound-Sensing Cells – Live Science

Posted: February 22, 2017 at 10:43 pm

Scientists have coaxed sound-sensing cells in the ear, called "hair cells," to grow from stem cells. This technique, if perfected with human cells, could help halt or reverse the most common form of hearing loss, according to a new study.

These delicate hair cells can be damaged by excessive noise, ear infections, certain medicines or the natural process of aging. Human hair cells do not naturally regenerate; so as they die, hearing declines.

More than 20 million Americans have significant hearing loss resulting from the death or injury of these sensory hair cells, accounting for about 90 percent of hearing loss in the United States, according to the Centers for Disease Control and Prevention.

In the new study, scientists at Harvard University and the Massachusetts Institute of Technology reported that they isolated stem cells from a mouse ear, discovered how to get them to multiply in a laboratory setting, and then converted them into hair cells. Their previous efforts, in 2013, produced only 200 hair cells. With a new technique, however, the research team has increased this number to 11,500 hair cells that were grown from one mouse ear. [Inside Life Science: Once Upon a Stem Cell]

Their paper describing the stem cell advance appears today (Feb. 21) in the journal Cell Reports.

Jeffrey Corwin, an expert on hair-cell regeneration and a professor of neuroscience at the University of Virginia School of Medicine, who was not part of this new research, called it "a very impressive studyby a dream team of scientists" and "a big advance" in the pursuit of regenerating these sensory hearing cells in humans.

Hair cells grow in bundles in the inner ear, and are so named because they look like hairs. Many hair cells within the ear are involved in balance, not hearing. But in the cochlea, the hearing organ deep in the ear canal, there are two kinds of specialized hair cells: outer hair cells, which amplify pitch and enable humans to discern subtle differences in sound; and inner hair cells, which convert sound into electrical signals sent to the brain. Humans have two cochleae (one in each ear), and each has only about 16,000 hair cells.

In fish, birds, lizards and amphibians, cochlear hair cells that die can be regenerated in as fast as a few days. However, in mammals, for the most part, the cells cannot regenerate except for mice and other small mammals when they are newly born. But since so many species can naturally regenerate hair cells from a stem cell precursor, including some newborn mammals, many researchers have been motivated to find a way to rekindle hair-cell regeneration in adult mammals and, of course, in humans, Corwin said.

The new research was done by a team led by Albert Edge, director of the Tillotson Cell Biology Unit at the Massachusetts Eye and Ear Infirmary and professor of otolaryngology at Harvard Medical School in Boston.

In 2012, Edge's group discovered stem cells in the ear called Lgr5+ cells. These cells are also found in the gut, where they actively regenerate the entire lining of human intestines every eight days. The research team soon found a way to coax the Lgr5+ cells to differentiate into hair cells, instead of intestinal cells. But the process was slow, and the yield was low.

Now, the researchers have increased the yield dramatically by inserting a new step. After removing Lgr5+ cells from mice, the researchers first get them to divide in a special growth medium. This step produced a two-thousandfold increase in Lgr5+ cells, Edge told Live Science. Then, the researchers moved these stem cells into a different kind of growth culture and added certain chemicals to turn the Lgr5+ cells into hair cells. [7 Ways the Mind and Body Change With Age]

These laboratory-grown hair cells appear to have many of the characteristics of actual inner and outer hair cells, although they might not be fully functional, Edge said. The most immediate use for this new technique will be to create a large set of the cells to test drugs and to identify compounds that can heal damaged hair cells or regrow them and restore hearing, Edge said.

Scientists have had difficulty testing drugs on large batches of actual hair cells because there are so few in mammalian ears and they are deep in the cochlea, hard to extract, Edge said.

The researchers have reason to believe the technique to regenerate fully functional hair cells in humans could someday work. As reported in their paper, the team tested the technique on a sample of healthy ear tissue from a 40-year-old patient who underwent a labyrinthectomy (removal of parts of the inner ear) to access a brain tumor. The adult human stem cells isolated from this tissue also multiplied and differentiated into hair cells, although not as robustly as the mouse cells did.

But as Corwin noted about Edge's research, "You can see in their paper that they are perfecting their technique as they go along."

Follow Christopher Wanjek @wanjekfor daily tweets on health and science with a humorous edge. Wanjek is the author of "Food at Work" and "Bad Medicine." His column, Bad Medicine, appears regularly on Live Science.

Read the original post:
Hear This: Scientists Regrow Sound-Sensing Cells - Live Science

Posted in Cell Medicine | Comments Off on Hear This: Scientists Regrow Sound-Sensing Cells – Live Science

Scientists identify chain reaction that shields breast cancer stem cells from chemotherapy – Medical Xpress

Posted: February 22, 2017 at 10:43 pm

February 22, 2017 Micrograph showing a lymph node invaded by ductal breast carcinoma, with extension of the tumour beyond the lymph node. Credit: Nephron/Wikipedia

Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.

The regrowth of cancer stem cells is responsible for the drug resistance that develops in many breast tumors and the reason that for many patients, the benefits of chemo are short-lived. Cancer recurrence after chemotherapy is frequently fatal.

"Breast cancer stem cells pose a serious problem for therapy," says lead study investigator Gregg Semenza, M.D., Ph.D., the C. Michael Armstrong Professor of Medicine, director of the Vascular Biology Program at the Johns Hopkins Institute for Cell Engineering and a member of the Johns Hopkins Kimmel Cancer Center. "These are the cells that can break away from a tumor and metastasize; these are the cells you most want to kill with chemotherapy. Paradoxically, though, cancer stem cells are quite resistant to chemotherapy."

Semenza says previous studies have shown that resistance to chemotherapy arises from the hardy nature of cancer stem cells, which are often found in the centers of tumors, where oxygen levels are quite low. Their survival is made possible through proteins known as hypoxia-inducible factors (HIFs), which turn on genes that help the cells survive in a low-oxygen environment.

In this new study, described Feb. 21 in Cell Reports, Semenza and his colleagues conducted gene expression analysis of multiple human breast cancer cell lines grown in the laboratory after exposure to chemotherapy drugs, like carboplatin, which stops tumor growth by damaging cancer cell DNA. The team found that the cancer cells that survived tended to have higher levels of a protein known as glutathione-S-transferase O1, or GSTO1. Experiments showed that HIFs controlled the production of GSTO1 in breast cancer cells when they were exposed to chemotherapy; if HIF activity was blocked in these lab-grown cells, GSTO1 was not produced.

Semenza notes that GSTO1 and related GST proteins are antioxidant enzymes, but GSTO1's role in chemotherapy resistance did not require its antioxidant activity. Instead, following exposure to chemotherapy, GSTO1 binds to a protein called the ryanodine receptor 1, or RYR1, that triggers the release of calcium, which causes a chain reaction that transforms ordinary breast cancer cells into cancer stem cells.

To more directly assess the role of GSTO1 and RYR1 in the breast tumor response to chemotherapy, the researchers injected human breast cancer cells into the mammary gland of mice and then treated the mice with carboplatin after tumors had formed. In addition to using normal breast cancer cells in the experiments, the team also used cancer cells that had been genetically engineered to lack either GSTO1 or RYR1. Loss of either GSTO1 or RYR1, the researchers report, decreased the number of cancer stem cells in the primary tumor, blocked metastasis of cancer cells from the primary tumor to the lungs, decreased the duration of chemotherapy required to induce remission and increased the duration of time after chemotherapy was stopped that the mice remained tumor-free.

Although the study showed that blocking the production of GSTO1 may improve the efficacy of chemotherapy drugs, such as carboplatin, GSTO1 is only one of many proteins that are produced under the control of HIFs in breast cancer cells that have been exposed to chemotherapy. The Semenza lab is working to develop drugs that can block the action of HIFs, with the hope that HIF inhibitors will make chemotherapy more effective.

Explore further: Toughest breast cancer may have met its match

More information: Haiquan Lu et al. Chemotherapy-Induced Ca2+ Release Stimulates Breast Cancer Stem Cell Enrichment, Cell Reports (2017). DOI: 10.1016/j.celrep.2017.02.001

Triple-negative breast cancer is as bad as it sounds. The cells that form these tumors lack three proteins that would make the cancer respond to powerful, customized treatments. Instead, doctors are left with treating these ...

Working with mice, Johns Hopkins researchers report they have identified chemical signals that certain breast cancers use to recruit two types of normal cells needed for the cancers' spread. A description of the findings ...

Working with human breast cancer cells and mice, scientists at The Johns Hopkins University say new experiments explain how certain cancer stem cells thrive in low oxygen conditions. Proliferation of such cells, which tend ...

Chemotherapy is a key part of the standard treatment regimen for triple-negative breast cancer patients whose cancer lacks expression of estrogen and progesterone receptors and the human epidermal growth factor receptor 2 ...

Existing chemotherapy approaches treat cancer by targeting cells that are actively multiplying and have a high metabolic rate. However, cancer stem cells can escape this targeting, leading to chemotherapy-resistant cancer ...

Conventional, high-dose chemotherapy treatments can cause the fibroblast cells surrounding tumors to secrete proteins that promote the tumors' recurrence in more aggressive forms, researchers at Taipei Medical University ...

Chemotherapy has long been standard treatment for many cancers, but its clinical benefits can also come with well-documented side effects. Doctors say the challenge is knowing which patients will experience these side effects, ...

Working with human breast cancer cells and mice, researchers at Johns Hopkins say they have identified a biochemical pathway that triggers the regrowth of breast cancer stem cells after chemotherapy.

In order for cancer to spread, malignant cells must break away from a tumor and through the tough netting of extracellular matrix, or ECM, that surrounds it. To fit through the holes in this net, those cancerous cells must ...

How we think and fall in love are controlled by lightning-fast electrochemical signals across synapses, the dynamic spaces between nerve cells. Until now, nobody knew that cancer cells can repurpose tools of neuronal communication ...

Researchers at the University of Pittsburgh School of Medicine have uncovered a novel genetic mechanism of thyroid cancer, as well as a marker that may predict response to a particular class of drugs, not just in patients ...

Treating multiple myeloma (MM) with myxoma virus (MYXV) eliminated a majority of malignant cells in preclinical studies, report investigators at the Medical University of South Carolina (MUSC) and elsewhere in an article ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more:
Scientists identify chain reaction that shields breast cancer stem cells from chemotherapy - Medical Xpress

Posted in Cell Medicine | Comments Off on Scientists identify chain reaction that shields breast cancer stem cells from chemotherapy – Medical Xpress

Stem Cell Therapy Could Reverse Hearing Loss – Seeker

Posted: February 22, 2017 at 10:42 pm

Humans have about 15,000 inner ear-hair cells, each one picking up sound vibrations, converting them to electric signals and sending them to the brain for processing.

Over time, loud noise, medications and old age combine to kill these cells and their microscopic hairs called stereocilia which leads to hearing loss. Unlike other animals, however, humans and mammals can't regrow them. But a group of scientists based in Boston say they've figured out a way to switch on the body's cellular factories and possibly reverse hearing loss.

"The biology is there, we just need to awaken it," said Jeffrey Karp, associate professor at Brigham and Women's Hospital, Harvard Medical School and an author on the new study appearing Tuesday in the journal Cell Reports. "For some reason there are brakes that we need to release for a short period of time to allow new hair cells to be produced."

RELATED: Can We Reverse Hearing Damage?

Karp and colleagues were able to regrow the hair cells by activating a stem cell in the cochlea called Lgr5 with a small molecule drug treatment. A similar stem cell is found in the human intestine and allows the body to regrow the exterior lining of the organ every five days.

The team also obtained a human cochlea from a patient who suffered from cancer and were able to regrow hair cells with their drug treatment.

"We don't want to provide false hope, but we are highly encouraged by this work. And our ability to produce bona fide functional hair cells is very compelling," Karp said.

The next step is taking the experimental data and starting a human clinical trial. Karp and Robert Langer of MIT are co-founders in a small startup firm, Frequency Therapeutics, that's working toward a phase I trial in the next 18 months, according to Karp.

A possible drug treatment for hearing loss could help the 360 million people worldwide who suffer from the condition.

RELATED: Why Does Loud Music Cause Hearing Loss?

"Their proposal is very novel and essentially by activating these supporting cells, a natural process will take over and a certain percentage would become hair cells capable of playing a role in the encoding of sound," said Nicolas Reed, an instructor in otolaryngology at the Johns Hopkins School of Medicine. "I don't see any obvious negative indications right now."

Hearing loss can lead to big problems as we age, including the onset of Alzheimer's disease, falls and social isolation, according to Larry Medwetsky, chairman of our Department of Hearing, Speech and Language Sciences at Gallaudet University.

"It is not a minor matter," Medwetsky said. "Hearing loss can affect you mentally and emotionally. If you can prevent or remediate it than you can also you can restore quality of life and avoid some of these issues."

WATCH: How Did Human Hearing Evolve?

Link:
Stem Cell Therapy Could Reverse Hearing Loss - Seeker

Posted in Cell Therapy | Comments Off on Stem Cell Therapy Could Reverse Hearing Loss – Seeker

Health Beat: Stem cell therapy for osteoarthritis – WFMZ Allentown

Posted: February 22, 2017 at 10:42 pm

Health Beat: Stem cell therapy for...

CHICAGO - As a professional photographer, climbing up step ladders and walking down stairs are part of the daily grind for 65-year-old Linda Schwartz.

"There's constant activity; you're moving the whole time, really," Schwartz said

But the pain of osteoarthritis in both of her knees was making all that activity a little harder.

"I tried cortisone shots. I had something called Euflexxa," Schwartz detailed. "I was sent to physical therapy twice. I mean, I did try acupuncture in my knees, but it didn't really seem to make a difference."

"It's like the rubber on the tire, so as you start to lose the rubber in your tire and the rim hits the road, that's what happens when you have bone on bone arthritis and you've lost all the cartilage in your knee," explained Dr. Adam Yanke, an orthopedic surgeon at Rush University Medical Center in Chicago.

Yanke enrolled Schwartz in an experimental new therapy that involved injecting amniotic fluid that contained stem cells donated by healthy mothers into the knees of osteoarthritis patients.

"Between the two of those, they're a potent anti-inflammatory and they also have growth factors that help promote healing or healthy growth of tissue," Yanke said.

It was, by far, the most effective pain treatment that Schwartz has tried. Unlike cortisone shots, there are no side-effects. The pain relief has so far lasted up to a year.

Research summary - Stem cell therapy for osteoarthritis

"It was a very gradual feeling of it's a little bit better, it's a little bit better, and then realizing, wow, it's really pretty good," said Schwartz.

The one drawback is the therapy is not for patients whose arthritis is so bad it requires knee replacement surgery. Even though it's still in the experimental stage, Yanke offers the stem cell treatment to his patients, but at a cost of $2,200 a shot, it is not yet covered by insurance.

Go here to read the rest:
Health Beat: Stem cell therapy for osteoarthritis - WFMZ Allentown

Posted in Cell Therapy | Comments Off on Health Beat: Stem cell therapy for osteoarthritis – WFMZ Allentown

VetStem Biopharma, Inc., Announces The Opening Of Its GMP Cell Therapy Manufacturing Facility – Laboratory Network

Posted: February 22, 2017 at 10:42 pm

VetStem constructed and validated a state-of-the-art GMP stem cell manufacturing plant at its headquarters laboratory in Poway, California

Poway,CA (PRWEB)- VetStem Biopharma, Inc., announced the opening of its GMP cell therapy manufacturing facility at its headquarters laboratory in Poway, California. Based upon 12 years of knowledge gained by following GTP laboratory guidelines and utilizing the experience of both in-house personnel and consultants, VetStem constructed and validated a state-of-the-art GMP stem cell manufacturing plant. This clean room facility has already produced three registration batches of stem cell product and those batches have been officially released for use in pivotal FDA studies of safety and efficacy.

Carolyn Wrightson, Ph.D., VP of Operations, stated, This facility is the culmination of six years of planning and research, supported by over 12 years of commercial stem cell laboratory operations by VetStems experienced cell therapy team. We believe this is the first dedicated veterinary-specific cell therapy facility in the United States. It will provide all the stem cell products for use in VetStem FDA product development programs. The facility operates under FDA GMP guidelines and is designed to produce commercial products, once approved by the FDA.

Quality is a critical element necessary to bring stem cell therapy into mainstream veterinary practice. VetStem has been committed to quality since its founding and has worked directly with the FDA Center for Veterinary Medicine since 2003 to assure our products and services adhere to the strictest guidelines for safety and efficacy, saidBob Harman, DVM, MPVM, CEOof VetStem. VetStem offers tours of this unique facility via large viewing windows in an exterior corridor and veterinarians are amazed at the high tech approach to veterinary cell therapy including the specialized approach to donor selection, disease screening, clean room cell culture and final packaging of the product in specialized cell product vials.

Stem cell therapy is a truly novel and natural approach to treatment of acute and chronic diseases in animals that have few or less efficacious therapeutic options. Using donor derived allogeneic stem cells provides cell therapy in a ready to use format without the need for tissue collection, or processing thus expanding the availability to more animals. VetStem is dedicated to providing affordable stem cell therapy for diseases of dogs, cats and horses, especially in areas of unmet needs, according to Harman.

About VetStem Biopharma VetStem Biopharma is a veterinarian-lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 14 years and 12,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The companys stated mission is to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases. In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 70 issued patents in the field of regenerative medicine.

Go here to read the rest:
VetStem Biopharma, Inc., Announces The Opening Of Its GMP Cell Therapy Manufacturing Facility - Laboratory Network

Posted in Cell Therapy | Comments Off on VetStem Biopharma, Inc., Announces The Opening Of Its GMP Cell Therapy Manufacturing Facility – Laboratory Network

An early signpost for type 1 diabetes? – Science Magazine

Posted: February 22, 2017 at 10:42 pm

Insulin-producing cells (yellow) produce the hormone insulin (green spheres) and are surrounded by other cells in the pancreas.

Carol and Mike Werner/Science Source

By Jennifer Couzin-FrankelFeb. 22, 2017 , 2:00 PM

Type 1 diabetes is one of the most common serious diseases to strike young children, but how does it start? Its a question that has bedeviled scientists for years. Now, a new study pinpoints a warning sign in healthy babies as young as 6 months old. The work could advance prevention efforts and might help explain the genesis of the autoimmune disease.

Type 1 diabetes hits when the body destroys insulin-producing cells in the pancreas. By the time peoplemany of them childrenare diagnosed, most of those cells are gone. Forty thousand new type 1 diabetes cases are recorded each year in the United States, and the disease is on the rise for reasons not well understood. A dream for diabetes researchers is to treat kids earlier, when they are headed down the diabetes road but arent yet there.

About 3 decades ago, scientists discovered a collection of signposts: antibodies directed at certain proteins in the body, including insulin. As they studied these children more intensively, they learned that those with two or more different kinds of these autoantibodies will eventually develop diabetes, though sometimes not for many years. Many clinical trials have since focused on trying to slow disease onset in these individuals.

But what happens before these autoantibodies arise? Ezio Bonifacio, a biologist at the Technische Universitt Dresden in Germany, had the means to tackle this question. He and his colleagues had for years been following children since birth whose genetics and family history put them at increased risk. Beginning in 2000, the researchers began to collect and store blood cells from a subset of these children. Recently, technology had advanced to the point that scientists could analyze single cells in those samples.

We decided that it was time to start to see if there was something happening at the level of the T cells, Bonifacio says. Commonly referred to as the sentries of our immune system, T cells are the villains in diabetes. They for some reason go rogue, leading the attack on insulin-producing cells in the pancreas.

Bonifacio and his colleagues performed sophisticated analysis on T cells from 12 babies who didnt develop autoantibodies latersuggesting they were in the clearand 16 babies who did. Probing the T cells in the lab, they saw that cells from the children who continued down the path toward type 1 diabetes were not normal. Essentially, when the T cells were exposed to a substance called an antigen, which in this case could trigger a response against insulin-producing cells, some of those T cells got activated. This is a faint echo of what happens inside the body of someone developing diabetes: Their T cells are activated against cells in the pancreas much as they would be against a foreign invader, like a virus.

These T cells have somehow already learnt to get halfway toward becoming autoreactive cells, says Bonifacio, whose team reports its findings today in Science Translational Medicine.

Bonifacio cautions that the findings are still preliminary. For one, samples like these from infancy are rare, and thus the number of children whose T cells were studied is modest. For another, although the unusual T cell behavior was entirely absent in kids who didnt get autoantibodies later on, it was recorded in only about half who did.

Still, the work breaks ground by identifying likely signs of type 1 diabetes studies earlier than ever, says Kevan Herold, an endocrinologist at Yale University, who studies ways to prevent the condition. The value of this paper is that theres stuff that can be measured even before the autoantibodies, agrees Gerald Nepom, director of the Immune Tolerance Network and former director of the Benaroya Research Institute in Seattle, Washington.

One central mystery is whats causing the changes in these cells so early in life. Bonifacio and others have looked exhaustively for environmental drivers of type 1 diabetes; although there have been hints of various influences, like certain infections, the punch line here is that the datas inconsistent across all the studies, says Carla Greenbaum, who chairs Type 1 Diabetes TrialNet, which oversees type 1 diabetes treatment and prevention trials, and directs the diabetes program at the Benaroya Research Institute.

So diabetes experts like Greenbaum have their eyes on prevention. Bonifacio is co-leading a study called Pre-POINT-Early, which offers oral insulin to children between 6 months and 2 years old; results are expected sometime next year. An oral insulin prevention study by TrialNet, in people with autoantibodies, will be reported in June. Herold hopes to report data in the near future on a study of an antibody called anti-CD3; he has tested it in newly diagnosed patients and is now trying it as a preventive.

Please note that, in an effort to combat spam, comments with hyperlinks will not be published.

Here is the original post:
An early signpost for type 1 diabetes? - Science Magazine

Posted in Diabetes | Comments Off on An early signpost for type 1 diabetes? – Science Magazine

This Kind of Fat Lowers Your Risk For Diabetes – TIME

Posted: February 22, 2017 at 10:42 pm

white yogurtGetty Images

Not all saturated fats are created equal, it appears. A pair of new studies suggests that certain sources of saturated fat may be worse than othersespecially when it comes to raising risk for type 2 diabetes.

In one study , published in the American Journal of Clinical Nutrition, researchers from Harvard University and the Universitat Rovira i Virgili in Spain tracked 3,349 Spanish adults for about 4.5 years. Overall, they found that people who consumed higher amounts of saturated fats and animal fats were twice as likely to develop diabetes than those who consumed a lower amount.

When the researchers broke down the results by specific food type, the consumption of butter (at 12 grams a day) and cheese (at 30 grams a day) were both linked to an increased risk of diabetes. On the other hand, people who ate whole-fat yogurt actually had a lower risk than those who didn't.

The researchers have several explanations for these findings. Yogurt contains healthful ingredients, like probiotics and protein, that may have protective effects when it comes to diabetes risk, says lead author Marta Guasch-Ferre, a nutrition research fellow at the Harvard T.H. Chan School of Public Health. Even though the results were adjusted to account for other food intake, unhealthy eating patterns may have influenced them. Butter and cheese often come with carbohydrates, like toast or crackers, Guasch-Ferre says. Plus, people who eat more yogurt tend to have better diets than those who dont, she adds.

The study did not find any significant links between diabetes risk and consumption of red meat, processed meat, eggs or whole-fat milk. That was a surprise to the researchers, who suspect that other factors may have diluted these results. They point out that dietary patterns in Spain are different than those in the United States, and that many of the study participants were following a Mediterranean diet, so these findings may not apply to someone following a typical American diet.

Its safe to say, based on the findings of other studies, that processed meat and red meat are associated with cardiovascular disease and other chronic disease risks, says Guasch-Ferre. We know its beneficial to reduce the intake of these meats and to replace them with healthy fats from plant sources like nuts and olive oil.

However, just because a fat may come from a plant doesn't make it healthy. Palm oil, used in a lot of processed foods, is very high in saturated fat. In another recent study, scientists demonstrate how even one dose of palm oil can affect metabolism and reduce the bodys sensitivity to insulin.

For this research, published in the Journal of Clinical Investigation, German scientists asked 14 healthy men to drink either a glass of plain water or a drink made with palm oil that contained as much saturated fat as a cheeseburger and French fries. When the participants drank one of these beverages, they experienced a reduction in insulin sensitivity, an increase in fat deposits in the liver and changes in their metabolism similar to those experienced by people with diabetes.

For healthy people, the authors say, the occasional fatty meal likely wont cause any permanent damage. But people who regularly eat foods high in palm oil or other saturated fats may face bigger long-term consequences, like chronic insulin resistance and fatty liver disease. Both are risk factors for diabetes.

The American Heart Association recommends that no more than 10% of total calories come from saturated fat and encourages consumption of unsaturated fats and carbohydrates from vegetables, fruits, whole grains, nuts and legumes. Based on recent research, says Guasch-Ferre, these recommendations seem to be just as important for diabetes risk as they are for heart healthand not just because fatty foods can cause weight gain.

I think its probably more that saturated fats have harmful effects on insulin resistance and other markers of inflammation, more than weight gain, she says. More research is needed, she adds, to fully understand the connection or to make clear recommendations about specific foods.

See the original post here:
This Kind of Fat Lowers Your Risk For Diabetes - TIME

Posted in Diabetes | Comments Off on This Kind of Fat Lowers Your Risk For Diabetes – TIME

Diabetes Psychosocial Care Addressed by ADA in First Published Recommendations – Endocrinology Advisor

Posted: February 22, 2017 at 10:42 pm

Diabetes Psychosocial Care Addressed by ADA in First Published Recommendations
Endocrinology Advisor
The American Diabetes Association (ADA) has released a position statement focused on aspects of psychosocial care in type 1 and type 2 diabetes, published in Diabetes Care.1 Based on current diabetes research and recommendations from mental and ...

Continue reading here:
Diabetes Psychosocial Care Addressed by ADA in First Published Recommendations - Endocrinology Advisor

Posted in Diabetes | Comments Off on Diabetes Psychosocial Care Addressed by ADA in First Published Recommendations – Endocrinology Advisor

Diabetes series begins on March 7 – Choteau Acantha

Posted: February 22, 2017 at 10:42 pm

Older adults are at a higher risk for diabetes and pre-diabetes than younger Americans. In fact, according to the Centers for Disease Control and Prevention (CDC), more than one in every four Americans over the age of 60 has diabetes, and with age comes greater risks for complications.

Diabetes can lead to heart attacks, strokes, blindness, kidney disease, amputations and even death.

However, studies show it is never too late to make changes to improve a persons health. Motivated adults ready to make lifestyle changes can slow the progression of diabetes and avoid or delay complications.

To help adults who want to get better control of their diabetes, Mountain-Pacific Quality Health, the Medicare quality innovative network-quality improvement organization (QIN-QIO) for Montana, Montana State University Teton County Extension and the Montana Geriatric Education Center are partnering together to offer a series of six, free diabetes classes.

These classes provide fun, informative and interactive ways to help people with diabetes or pre-diabetes (high blood sugar).

Understand diabetes and how it affects the entire body;

Manage diabetes in a way that makes sense for them and their individual health goals;

Become more informed members of their health care teams, as they continue to work with their doctors, diabetes educators and other health care providers to improve their health.

The classes support, not replace, professional self-management diabetes education. While the classes are designed for people with Medicare, anyone with diabetes or pre-diabetes is welcome to attend.

The series kicks off March 7, from 6:45 to 7:45 p.m., in the Alice Gleason room at the Choteau/Teton Public Library at 17 Main Ave. N. Classes will then meet every Tuesday through April 18, excluding March 21. Anyone interested in attending these classes can register by calling 466-2492 or emailing to teton@montana.edu.

See the original post here:
Diabetes series begins on March 7 - Choteau Acantha

Posted in Diabetes | Comments Off on Diabetes series begins on March 7 – Choteau Acantha

Page 1,662«..1020..1,6611,6621,6631,664..1,6701,680..»